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DObjectives: To study the determinants of functional tricuspid regurgitation (TR) progression after surgical
correction of mitral regurgitation, including the influence of mitral valve (MV) repair (MVr) versus replacement
(MVR) for degenerative mitral regurgitation.
Methods: From January 1995 to January 2006, 747 adults with MV prolapse underwent isolated MVr (n¼ 683)
or MVR (n ¼ 64; mechanical in 32). The mean age was 60.8 years, and 491 were men (66.0%). Moderate
preoperative functional TR was present in 115 (15.4%). The MVR group had a greater likelihood of
New York Heart Association class III or IV (75.0% vs 34.4%, P<.001), atrial fibrillation (20.3% vs 8.3%,
P¼ .002), a lower left ventricular ejection fraction (61.0% vs 65.2%, P<.003), and a higher pulmonary artery
pressure (50.1 vs 41.2 mmHg, P¼ .001). The patients were monitored for a mean of 6.9 years (MVr) or 7.7 years
(MVR; P ¼ .075).
Results: During late follow-up, no difference was found between the groups in the development of moderately
severe or severe TR: 1 to 5 years (3.0% vs 3.3%, P¼ .91) and>5 years (6.1% vs 6.5%; P¼ .93). The univariate
predictors of severe TR after 5 years were older age (hazard ratio [HR], 1.1; P¼ .011), female gender (HR, 6.86;
P¼ .005), higher pulmonary artery pressure (HR, 1.05; P¼ .022), and larger left atrial size (HR, 2.11; P¼ .035).
Two patients (0.26%) who had undergone initial MVr required reoperation for late functional TR. Another 2
patients had had the tricuspid valve addressed concurrent with reoperation for MVr failure. No tricuspid
reoperations were required in the MVR group.
Conclusions: The risk of TR progression was low after MVr or MVR for MV prolapse. Timely MV surgery
before the development of left atrial dilatation or pulmonary hypertension could further decrease the risk of
TR progression during follow-up. (J Thorac Cardiovasc Surg 2014;148:1957-62)See related commentary on pages 1962-4.Tricuspid valve (TV) regurgitation may occur either from a
primary anatomic abnormality of the TVapparatus or, more
commonly, secondary to annular dilatation (functional)
associated with left-sided heart valve disease. Functional
TV regurgitation (TR) is often dynamic and can vary with
both pulmonary artery pressure and left sided heart valve
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The Journal of Thoracic and CarThe concomitant correction of moderately severe or
severe TR at mitral valve (MV) surgery is most always
performed and is well supported by the contemporary
evidence.2-5 In contrast, asymptomatic moderate or less
functional TR associated with left-sided heart disease in
the setting of a normal right ventricular (RV) size and func-
tion may, at times, stabilize or regress after correction of
left-sided heart pathologic entities. Thus, whether the TV
should be addressed in such situations has remained contro-
versial.6,7 The debate has centered, in part, around the
theoretical concern of the risk of delayed progression of
TR after isolated correction of mitral regurgitation (MR)
necessitating high-risk surgical re-intervention. Despite
the existence of strongly held beliefs on this topic long-
term studies of a homogeneous population of patients
with degenerative MR have been lacking.1,5,8-11 It has
also been unclear whether MV repair (MVr) or
replacement (MVR) influences the likelihood of late TR
progression. We, thus, sought to study the progression and
late outcomes of preoperatively identified functional TR
after surgical correction of MV prolapse. Our aim was to
test the null hypothesis that moderate or less functional
TR always progresses, necessitating reoperation, and is
influenced by the performance of MVr versus MVR.diovascular Surgery c Volume 148, Number 5 1957
Abbreviations and Acronyms
HR ¼ hazard ratio
LA ¼ left atrial
MR ¼ mitral regurgitation
MV ¼ mitral valve
MVr ¼ mitral valve repair
MVR ¼ mitral valve replacement
RA ¼ right atrial
RV ¼ right ventricular
TR ¼ tricuspid regurgitation
TV ¼ tricuspid valve




Patients undergoing surgical correction of isolated myxomatous MR
(all caused by degenerative leaflet prolapse) from January 1995 to January
1, 2006 at the Mayo Clinic (Rochester, Minn) were studied, after review
and approval from the Mayo Clinic institutional review board. A total of
747 patients>18 years old had undergone isolated surgical correction of
MR due to degenerative leaflet prolapse using eitherMVr orMVR. Patients
with primary TV disease, right-sided heart failure symptoms, previous TV
intervention, or nondegenerative mitral pathologic entities (ie, rheumatic,
ischemic, congenital, radiation-induced, pericardial constriction) were
excluded from the present study because they had most frequently
undergone concomitant TV repair. During the same period, 302 patients
had undergone MVR plus TV repair and were not included in the present
analysis. Our institutional indications for TV interventions concurrent
with degenerative MVR are as follows:
1. Moderately severe or severe TR
2. Right-sided heart failure symptoms with moderate or severe TR
3. Moderate TR with one of the following: primary TV disease, structural
abnormalities of the TV (including impingement of the tricuspid leaflets
by pacemaker leads), a dilated right atrium and right ventricle, severe
pulmonary hypertension, or atrial fibrillation
Those patientswho had undergone additional procedures aside frompat-
ent foramenovale closurewere not included in the present study to avoid the
potential influence on TR. Patients requiring placement of a transvenous
pacing lead through the TV before the index operation or during the postop-
erative period were also excluded. The presence of the lead itself and the
performance of ventricular pacing can both accentuate TR; thus, our policy
has been to more aggressively correct TR in this setting. Patients with pri-
mary lung disease were also excluded from the present study.
TR was assessed using transthoracic echocardiography preoperatively
and during follow-up to ascertain progression after MV surgery. MR
severity was determined by the assessment of the origin of the regurgitant
jet, width (vena contracta) of the jet, effective orifice area, and spatial
regurgitant jet area in the receiving chamber. The regurgitant jet radius
was also measured, using the proximal isovelocity surface area method in
some instances. Functional TR was defined as TR without any anatomic
abnormality of the TV leaflets or subvalvar apparatus. TR was quantified
from the echocardiographic findings as grade 1 (trace), grade 2 (mild), grade
3 (moderate), and grade 4 (moderately severe or severe). The TR data were
analyzed preoperatively and during follow-up at 1, 1 to 5, and after 5 years.
Statistical Analysis
The descriptive statistics for categorical variables are reported as fre-
quencies and percentages and continuous variables as the mean  standard
deviation or median and ranges, as appropriate. The categorical variables
were compared between the MVR and MVr groups using the chi-square1958 The Journal of Thoracic and Cardiovascular Surtest or Fisher’s exact test. Continuous variables were compared using the
2-sample t test or Wilcoxon rank sum test, as appropriate.
The Kaplan-Meier method was used to draw the survival curves and
calculate the 5- and 10-year survival statistics. Cox regression models
were used to find the univariate and multivariate predictors of survival.
The multivariate model included the variables significant on univariate
analysis (P < .05), with model selection using the stepwise method
(backward and forward methods resulted in the same model). Univariate
logistic regression models were used to find the univariate predictors for
the occurrence of TR grade 4 at 1 to 5 years and 5 years of follow-up.
All statistical tests were 2-sided, with the a level set at 0.05 for statistical
significance.RESULTS
Baseline Characteristics
A total of 683 patients (91.4%) underwent MVr and 64
(8.6%) had MVR. Of the 747 patients, 491 were male
(66.0%) and 256 were female (34.0%). The preoperative
demographics are listed in Table 1. Slight differences
were found between the 2 groups, with the MVR patients
older (65.7  13.4 vs 60.4  13.7 years, P ¼ .002) and
more likely to have New York Heart Association class III
or IV symptoms (75.0% vs 34.4%, P<.001), atrial fibril-
lation (20.3% vs 8.3%, P ¼ .002), a lower left ventricular
ejection fraction (61.0%  10% vs 65.2%  8%,
P ¼ .003), and a higher pulmonary artery pressure
(50.1  19 vs 41.2  14 mm Hg, P ¼ .001).Operative Characteristics
MVr was performed using conventional valvuloplasty
techniques (Table 2). All patients had a standard length
posterior annuloplasty band placed during MVr. The
MVR group had a mechanical valve placed in 32 patients
(50.0%). MVr had initially been attempted in 15 patients
(23.0%) in the MVR group within this historic series.Early Complications and Late Survival
The early complications are listed in Table 2. There were
4 early deaths (0.6%) after MVr and 1 (1.6%) after MVR
(P ¼ .362). The patients were followed up for mean period
of 7.0  3.9 years (MVr, 6.9  3.9 years; MVR, 7.7  3.8
years; P ¼ .075).Presence of Postoperative Moderately Severe or
Severe Symptomatic TR and Surgical Intervention
The presence of moderately severe or severe TR was
assessed at 1, 1 to 5, and after 5 years (Table 3). The
completeness of echocardiographic follow-up for the
patients at risk at these periods was 238 of 673 patients
(35.4%) at<1 year, 275 of 564 patients (48.8%) at 1 to 5
years, and 200 of 249 patients (80.3%) at>5 years. During
the follow-up period, the incidence of grade IV TR
was similarly low among the MVr and MVR groups at
<1 year (2.5% vs 7.7%, P ¼ .264), 1 to 5 years (3.0% vs
3.3%, P ¼ .915), and>5 years (6.1% vs 6.5%, P ¼ .934).gery c November 2014










Age (y) 60.8  13.7 60.4  13.7 65.7  13.4 .002
Gender .770
Male 491 (66) 450 (65.9) 41 (64.1)
Female 256 (34) 233 (34.1) 23 (35.9)
NYHA class <.001
I and II 464 (62.1) 448 (65.6) 16 (25)
III and IV 283 (37.9) 235 (34.4) 48 (75)
Hypertension 288 (39) 270 (39.5) 18 (28.1) .073
Diabetes 19 (3) 18 (2.6) 1 (1.6) .602
Preoperative atrial
fibrillation
70 (9) 57 (8.3) 13 (20.3) .002
EF (%) 64.9  7.8 65.2  7.6 61.0  9.8 .003
LVEDD (mm) 57.8  7.1 58.1  6.3 53.0  15.1 .101
LVESD (mm) 35.3  7.1 35.4  5.9 32.8  11.5 .814
MR — — —
Grade III 50 (7)
Grade IV 697 (93)
Preoperative TR .790
Grade I and II 598 (80.0) 570 (83.5) 28 (43.8)
Grade III 115 (15.4) 110 (16.1) 5 (7.8)
No TR 34 (4.6) 3 (0.4) 31 (48.4)
RVSP (mm Hg) 41.75  14.8 41.2  14.3 50.1  18.6 .001
Data presented as mean  standard deviation or n (%). MVr, Mitral valve repair;
MVR, mitral valve replacement; NYHA, New York Heart Association; EF, ejection
fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular
end-systolic dimension; MR, mitral regurgitation; RVSP, right ventricular systolic
pressure; TR, tricuspid regurgitation.
TABLE 2. Intraoperative and postoperative characteristics
Variable Value P value
MVr
Posterior leaflet resection 496 (70.6)
Chordae transfer 32 (4.7)
Artificial chordae 104 (15.2)
Edge to edge repair 17 (2.5)
MVR
Tissue valve 32 (50.0)
Mechanical valve 32 (50.0)




Minimally invasive approach, minithoracotomy —
MVr 8 (1.2)
MVR 0 (0)
Aortic crossclamp time (min) <.001
MVr 36.2  16.5
MVR 63.6  25.3
Extracorporeal circulation time (min) <.001
MVr 51.6  24.9






















Data presented as mean  standard deviation or n (%). MVr, Mitral valve repair;
MVR, mitral valve replacement; PFO, patent foramen ovale; AF, atrial fibrillation;
PPM, permanent pacemaker.
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DWe addressed the TV during our follow-up period in
4 patients. Two patients required isolated TV replacement,
one at 4 years and one at 14 years after MVr. Two patients
had the TV addressed at the time of MV reoperation.
The recurrence of MR was low and similar between the 2
groups (Table 3). The prevalence of heart failure symptoms
was greater in the MVR group up to the 5-year follow-up
point. After 5 years, the incidence of heart failure symptoms
was similar in both groups (1.9% vs 3.7%, P ¼ .544). The
predictors of the presence of grade IV functional TR at 1 to
5 years and after 5 years are listed in Table 4 and included
advanced age (P ¼ .011), female gender (P ¼ .005),
elevated pulmonary pressure (P ¼ .022), and increased
left atrial (LA) size (P¼ .035). MVR was not a statistically
significant univariate predictor for progression of functional
TR at any point during the follow-up period. Patients with
preoperative atrial fibrillation were 4.58 times more likely
to experience TR progression late after MVr; however,
this did not reach statistical significance in the present
analysis (P ¼ .054). None of these factors were significant
independent predictors on multivariate analysis of late TR
during follow-up at 1 to 5 or after 5 years.
DISCUSSION
Functional TR has been shown to exist in 30% of
patients undergoing isolated MV surgery.4,8 In our study,The Journal of Thoracic and Carmost patients with degenerative MV prolapse had minimal
or no TR while 115 patients (15%) had more than mild
TR at index mitral operation. Importantly, no difference
was found in the development of moderately severe or
severe TR or heart failure symptoms after 5 years despite a
decision not to address moderate-or-less TR. We found
that the unadjusted predictors of TR progression after 5
years were older age, female gender, higher preoperative
pulmonary artery pressure, and larger LA size. Takendiovascular Surgery c Volume 148, Number 5 1959
TABLE 3. Comparison of postoperative presence of MR, TR, and
symptoms between MVr and MVR
Follow-up point MVr MVR P value
<1 y
MR grade I-III 220 (98.7) 12 (100) .686
MR grade IV 3 (1.3) 0 (0)
TR grade I-III 199 (97.6) 12 (92.3) .264
TR grade IV 5 (2.5) 1 (7.7)
NYHA class I and II 55 (98.2) 13 (86.7) .048
NYHA class III and IV 1 (1.8) 2 (13.3)
1-5 y
MR grade I-III 241 (98.4) 26 (96.3) .447
MR grade IV 4 (1.6) 1 (3.7)
TR grade I-III 228 (97.0) 29 (96.7) .915
TR grade IV 7 (3.0) 1 (3.3)
NYHA class I and II 82 (98.8) 27 (90) .026
NYHA class III and IV 1 (1.2) 3 (10)
>5 y
MR grade I-III 165 (97.6) 23 (100) .456
MR grade IV 4 (2.4) 0 (0)
TR grade I-III 155 (93.9) 29 (93.5) .934
TR grade IV 10 (6.1) 2 (6.5)
NYHA class I and II 157 (98.1) 26 (96.3) .544
NYHA class III and IV 3 (1.9) 1 (3.7)
Data presented as n (%). MR, Mitral regurgitation; TR, tricuspid regurgitation;
MVr, mitral valve repair; MVR, mitral valve replacement; NYHA, New York Heart
Association.
TABLE 4. Risk factors for development of late grade IV tricuspid
regurgitation
Risk factor
1-5 y >5 y
HR (95% CI)
P
value HR (95% CI)
P
value
Age 1.12 (1.02-1.22) .017 1.1 (1.02-1.17) .011
Female gender 2.34 (0.57-9.59) .24 6.86 (1.79-26.29) .005
Preoperative AF 2.43 (0.47-12.57) .29 4.58 (0.98-21.48) .054
Preoperative TR
grade>2
14.63 (2.85-75.08) .001 2.74 (0.75-9.97) .130
Preoperative EF 0.93 (0.87-1) .041 1 (0.93-1.07) .990
Preoperative RVSP 1.04 (1.01-1.08) .017 1.05 (1.01-1.09) .022
Preoperative RA size 2.06 (0.97-4.38) .06 1.53 (0.84-2.79) .160
Preoperative LA size 1.25 (0.59-2.62) .56 2.11 (1.05-4.21) .035
Preoperative RV size NA NA 3.75 (0.9-15.66) .070
MVR 1.12 (0.13-9.46) .915 1.07 (0.22-5.13) .934
HR, Hazard ratio; CI, confidence interval; AF, atrial fibrillation; TR, tricuspid
regurgitation; EF, ejection fraction; RVSP, right ventricular systolic pressure;
RA, right atrial; LA, left atrial; RV, right ventricular; NA, not applicable; MVR, mitral
valve replacement.
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Dtogether, these data suggest that the timing ofMVr for severe
chronic degenerativeMR could possibly be influential in the
progression of moderate or less functional TR, identified at
surgical correction of severe degenerative MR. Definitive
conclusions will necessarily await the incorporation of
additional markers of chronicity in future analyses, to
determine which are most influential in avoiding the onset
and progression of functional TR.
Conflicting data have been published regarding the
progression of uncorrected moderate-or-less TR, varying
from minor to significant consequences on morbidity and
mortality. Those opting not to correct functional TR have
inferred that annular dilatation and RV enlargement might
eventually regress over time after correction of left-sided
heart pathologic entities,6,7 but others have related that
delayed progression of TR might adversely effect late
patient survival.2,5,9 Nath and colleagues9 demonstrated
that the 1-year survival of patients will be adversely affected
is impacted by the presence and severity of TR, which has
led to renewed interest in the correction of moderate TR
at MV surgery.2,4
Although the progression of TR has been documented for
patients with rheumatic mitral disease12 and those with
ischemic mitral valve pathology,13 this might not hold
true for all MV disease etiologies. Yilmaz and colleagues,14
in a review of patients with degenerative MV disease who
had undergone MVr from our institution did not find that1960 The Journal of Thoracic and Cardiovascular Sursignificant TR progression occurred after surgery in this
specific population. Only 1 patient required surgical TR
correction during the follow-up period. We hypothesized
that patients with MV leaflet prolapse might be more likely
to undergo earlier MVr, thus avoiding the development of
severe distortion of the RV geometry that appears
etiologic in the insidious and irreversible progression of
functional TR.14 Supporting this hypothesis, Benedetto
and colleagues15 did not find a statistically significant
advantage for TVannuloplasty in patients with degenerative
MV disease, although TV repair provided a benefit in those
with rheumatic and ischemic MV pathologic features.
We believe that the role of MV disease etiology in the
progression of TR might be underappreciated and might
be more influential in the progression of TR after MV
surgery. Most published studies reporting TR progression
after MV surgery have either studied functional TR in
heterogeneous categories of patients (rheumatic, ischemic,
radiation-induced, congenital, inflammatory) or have failed
to stratify by etiology.2,8,12,13,15-17 That we studied a
homogenous group of patients with degenerative MR is
unique and entails that the results are directly applicable
to a large population of patients presenting for early
mitral valve surgery in contemporary cardiac surgical
practice.
The factors known to result in the persistence or
progression of TR are age,3,8,18-20 female gender,3,14,18
preoperative left ventricular and RV function,8,16,20 and
atrial fibrillation.4,14,16,20,21 Atrial fibrillation has long
been recognized as an important predictor of the
development of TR.4,14,16 Enlarged left and right atria
predispose to atrial fibrillation and, in turn, could
influence the development of tricuspid incompetence.16,22
In the present study, although a trend was seen forgery c November 2014
Rajbanshi et al Acquired Cardiovascular Disease
A
C
Dpreoperative atrial fibrillation to predict the development of
postoperative TR (hazard ratio [HR], 2.43 and P ¼ .29 at
1-5 years; HR, 4.58 and P ¼ .054 at>5 years), it did not
reach statistical significance, which we have previously
demonstrated.14,23 We also assessed the LA, right atrial
(RA), and RV size as risks of TR progression. Although
the preoperative LA size was a significant predictor at>5
years (HR, 2.11; P ¼ .035), none of the other factors
appeared to be influential, although an enlarged RA size
was close to statistical significance for TR progression at
1 to 5 years (HR, 2.06; P ¼ .06) and>5 years (HR, 3.75;
P ¼ .07). He and colleagues22 have suggested repair of
functional TR when the right atrium and ventricle are
dilated. They recommended addressing the TV when the
RA diameter is>57 mm, the RV end-systolic diameter is
>55 mm, and pulmonary artery pressure is>58 mm Hg.
Our study was not designed to test this recommendation.
It is difficult to predict which patients will develop
progression or regression of functional TR following
successful elimation of severe degenerative MR. Repair of
moderate functional TR is an American College of
Cardiology/American Heart Association guideline class
IIB recommendation when associated with pulmonary
hypertension or annular dilatation (level of evidence C); it
is a class IIA indication in the presence of a dilated
annulus as a concomitant procedure according to the
European Society of Cardiology guidelines.24,25 Various
investigators have advocated TV repair when annular
dilatation is present.15,19,21 Groves and colleagues26
suggested that once the annulus has become enlarged, a
minimal further increase will be associated with significant
TR progression. Thus, treating the MV lesion alone in such
patients will only reduce the afterload and will not
necessarily alter TV annular dilatation or improve RV
function and, thus, would not eliminate the substrate for
TR persistence or progression.4 Although we did not
historically measure the TV annular dimension, patients
were included in our present study if they had normal RV
size and function. The derived conclusions will thus be
applicable to this specific population of patients.
The limitations of the present study were consistent with
its retrospective nature. A prospective randomized study
would not be plausible, because MVr continues to be the
preferred procedure over MVR. Also, recent evidence has
confirmed that early MVr in the absence of symptoms
improves long-term survival.27 Although we monitored
TR on clinically indicated echocardiograms, it is possible
that those with significant TR evaded detection. However,
this possibility was unlikely owing to the typically robust
follow-up in our referral network and that right-sided
heart failure associated with severe TR typically detected
on physical examination depite the fact that symptoms
may be more difficult to quantify. Also, the patients seen
in follow-up at our valvular heart disease clinics haveThe Journal of Thoracic and Carechocardiograms readily available, and assessment of
both left- and right-sided heart function is routinely
performed.CONCLUSIONS
Our results have shown that moderate or less TR in
patients undergoing isolated surgical correction of
degenerative MR is unlikely to progress in the absence of
symptoms, concomitant cardiac disease, right-sided heart
failure, an increased LA size, or pulmonary hypertension.
The risk of TR progression was similarly low after either
MVr or MVR in this historic series. Age, gender, and the
timing of MV surgery could all potentially influence the
progression of functional TR; however, definitive
conclusions will necessarily await the incorporation of
additional markers of chronicity in future analyses. A
thoughtful, individualized approach based upon available
evidence relevant to specific disease-based population
being discussed, remains essential in deciding when
correction of moderate-or-less functional TR is required.References
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2013;310:609-16.MMENTARY‘‘Forgotten’’ valve or ‘‘enigmatic’’ valve? Further insights into the
tricuspid valve in patients undergoing mitral valve surgeryElizabeth H. Stephens, MD, PhD, and Michael A. Borger, MD, PhDCommonly referred to as the ‘‘forgotten valve,’’ the
tricuspid valve (TV) has received increasing attention in
recent years.1 Functional tricuspid regurgitation (fTR)
was often overlooked in the past, both because correction
of left-sided valvular pathology was thought to sufficiently
ameliorate fTR and because the optimal TV repair tech-
nique was unknown. We now know that fTR does not al-
ways improve after left-sided surgery and that residualtricuspid regurgitation (TR) imparts a poor long-term prog-
nosis. Residual TR is associated with a 2-fold risk of heart
failure1 and a 50% decrease in 5-year survival.2 Residual
TR is also progressive, with one-half of all patients having
progression by more than 2 grades 5 years after surgery.3 In
addition, isolated TV surgery for TR is associated with un-
acceptably high morbidity and mortality after mitral valve
(MV) surgery.4
In light of these findings, some investigators have argued
strongly for concomitant TV repair for patients with any
amount of fTR—or even for those with isolated tricuspid
annular dilation without fTR—when they undergo left-sided
valvular surgery.5 Several different tricuspid annuloplasty
rings have been designed for fTR, with none demonstrating
clear clinical superiority to date. Some evidence suggests,
however, that flexible rings may be associated with a lower
risk of dehiscence relative to rigid rings.6 Determining which
criteria should be applied to performing TV repair in patients
undergoing MV surgery remains a topic of debate.
Current guidelines recommend that severe TR should
be addressed at the time of MV surgery,7,8 because TVgery c November 2014
